Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis
Pharmaceuticals · 05.08.2024 · 17 (8) · 1028
DOI: 10.3390/ph17081028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 05.08.2024. Verfasst von Wenting Zhang und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy department, Dawning Program of Wuhan Knowledge Innovation Special Project, National Natural Science Foundation of China.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background: Adalimumab has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult rheumatoid arthritis (RA), and subsequently approved for pediatric treatment of various autoimmune diseases in children of different ages. Due to genetic differences between children and adults in terms of physiology and immunity, there is a need to explore the safety of adalimumab in children in the real world. The aim of this study is to identify potential adverse event (AE) signals associated with the use of adalimumab in pediatric patients (
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Pharmacy, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.
- Department of Clinical Pharmacy, General Hospital of Central Theater Command of Chinese People's Liberation Army, Wuhan 430060, China.
- Department of Pediatric Gastroenterology and Infection, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1095 Jiefang Avenue, Wuhan 430030, China.
- Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, No. 1277 Jiefang Avenue, Wuhan 430022, China.
ORCID-Profile: Qilin Zhang
Förderung
- Talent Project established by Chinese Pharmaceutical Association Hospital Pharmacy department
- Dawning Program of Wuhan Knowledge Innovation Special Project
- National Natural Science Foundation of China
Zitieren
APA
Zhang, W., Xu, Z., Shu, Y., Shu, S., & Zhang, Q. (2024). Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis. Pharmaceuticals, 17(8), 1028. https://doi.org/10.3390/ph17081028
Vancouver
Zhang W, Xu Z, Shu Y, Shu S, Zhang Q. Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis. Pharmaceuticals. 2024;17(8):1028. doi:10.3390/ph17081028
BibTeX
@article{Zhang2024,
author = {Zhang, Wenting and Xu, Ziqi and Shu, Yamin and Shu, Sainan and Zhang, Qilin},
title = {Adverse Event Profiles of Adalimumab in Children: A Disproportionality Analysis},
journal = {Pharmaceuticals},
year = {2024},
volume = {17},
number = {8},
pages = {1028},
doi = {10.3390/ph17081028}
}
EUVIMED